Active, Not Recruiting
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy - CA209-7HX
Uppdaterad:
19 maj, 2023
|
ClinicalTrials.gov
Kön
Åldersintervall
Active, Not Recruiting
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Pathologically confirmed diagnosis of advanced NSCLC - Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label - Previously treated with at least one prior chemotherapy- containing regimen Exclusion Criteria: - Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs - Participants with a diagnosis of another primary cancer within the past five years - Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study Other protocol-defined inclusion/exclusion criteria apply
Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information
466-SE-2100058